News
Novo Nordisk's Wegovy Showdown: Navigating Market Pressures and Potential Layoffs
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job cuts. Despite lucrative past sales, Novo warns of slower growth due to rival generics and compounding pharmacies,
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
22hOpinion
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback